| A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma TE Witzig, CB Reeder, BR LaPlant, M Gupta, PB Johnston, IN Micallef, ... Leukemia 25 (2), 341-347, 2011 | 367 | 2011 |
| BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells S Chu, M Holtz, M Gupta, R Bhatia Blood 103 (8), 3167-3174, 2004 | 205 | 2004 |
| Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation M Gupta, JJ Han, M Stenson, M Maurer, L Wellik, G Hu, S Ziesmer, ... Blood, The Journal of the American Society of Hematology 119 (12), 2844-2853, 2012 | 204 | 2012 |
| Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study SM Ansell, H Tang, PJ Kurtin, PA Koenig, DJ Inwards, K Shah, ... The lancet oncology 12 (4), 361-368, 2011 | 190 | 2011 |
| Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2 M Gupta, SM Ansell, AJ Novak, S Kumar, SH Kaufmann, TE Witzig Blood, The Journal of the American Society of Hematology 114 (14), 2926-2935, 2009 | 183 | 2009 |
| Gadd45a and Gadd45b protect hematopoietic cells from UV-induced apoptosis via distinct signaling pathways, including p38 activation and JNK inhibition M Gupta, SK Gupta, B Hoffman, DA Liebermann Journal of Biological Chemistry 281 (26), 17552-17558, 2006 | 175 | 2006 |
| Hematopoietic cells from Gadd45a-and Gadd45b-deficient mice are sensitized to genotoxic-stress-induced apoptosis M Gupta, SK Gupta, AG Balliet, MC Hollander, AJ Fornace, B Hoffman, ... Oncogene 24 (48), 7170-7179, 2005 | 153 | 2005 |
| The long non-coding RNA GAS5 cooperates with the eukaryotic translation initiation factor 4E to regulate c-Myc translation G Hu, Z Lou, M Gupta PloS one 9 (9), e107016, 2014 | 147 | 2014 |
| Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy M Gupta, JJ Han, M Stenson, L Wellik, TE Witzig Leukemia 26 (6), 1356-1364, 2012 | 140 | 2012 |
| The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma TE Witzig, C Reeder, JJ Han, B LaPlant, M Stenson, HW Tun, W Macon, ... Blood, The Journal of the American Society of Hematology 126 (3), 328-335, 2015 | 121 | 2015 |
| Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies M Gupta, AEW Hendrickson, SS Yun, JJ Han, PA Schneider, BD Koh, ... Blood, The Journal of the American Society of Hematology 119 (2), 476-487, 2012 | 121 | 2012 |
| Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma MJ Maurer, INM Micallef, JR Cerhan, JA Katzmann, BK Link, JP Colgan, ... Journal of clinical oncology 29 (12), 1620-1626, 2011 | 107 | 2011 |
| Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors W Li, SK Gupta, W Han, RA Kundson, S Nelson, D Knutson, PT Greipp, ... Journal of hematology & oncology 12 (1), 73, 2019 | 88 | 2019 |
| RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2 U Dahal, K Le, M Gupta Melanoma research 29 (4), 382-389, 2019 | 75 | 2019 |
| Hematopoietic cells from gadd45a-deficient and gadd45b-deficient mice exhibit impaired stress responses to acute stimulation with cytokines, myeloablation and inflammation SK Gupta, M Gupta, B Hoffman, DA Liebermann Oncogene 25 (40), 5537-5546, 2006 | 70 | 2006 |
| Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP M Gupta, MJ Maurer, LE Wellik, ME Law, JJ Han, N Ozsan, IN Micallef, ... Blood, The Journal of the American Society of Hematology 120 (22), 4400-4406, 2012 | 66 | 2012 |
| t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth SM Ansell, T Akasaka, E McPhail, M Manske, E Braggio, T Price-Troska, ... Blood, The Journal of the American Society of Hematology 120 (19), 3949-3957, 2012 | 61 | 2012 |
| A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase–regulated mammalian target of … M Gupta, SR Dillon, SC Ziesmer, AL Feldman, TE Witzig, SM Ansell, ... Blood, The Journal of the American Society of Hematology 113 (21), 5206-5216, 2009 | 61 | 2009 |
| Signal transduction inhibitor therapy for lymphoma TE Witzig, M Gupta Hematology 2010, the American Society of Hematology Education Program Book …, 2010 | 59 | 2010 |
| Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas TE Witzig, H Tang, INM Micallef, SM Ansell, BK Link, DJ Inwards, ... Blood, The Journal of the American Society of Hematology 118 (18), 4882-4889, 2011 | 52 | 2011 |
